CIBC Asset Management
CARM

CIBC Asset Management’s Carisma Therapeutics CARM Stock Holding History

CIBC Asset Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14,971
Closed -$34K – 1155
2024
Q1 		$34K Hold
14,971
– – ﹤0.01% 1115
2023
Q4 		$43.9K Hold
14,971
– – ﹤0.01% 1078
2023
Q3 		$63.3K Hold
14,971
– – ﹤0.01% 1017
2023
Q2 		$131K Hold
14,971
– – ﹤0.01% 1012
2023
Q1 		$46.4K Buy
+14,971
New +$143K ﹤0.01% 1030

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CIBC Asset Management's CARM Position: Q2 2024 in Review

CIBC Asset Management sold out of Carisma Therapeutics (CARM) in Q2 2024, closing a stake of 14,971 shares — an estimated $34K sold.

CIBC Asset Management first reported a position in CARM in Q1 2023 and held it in 5 quarters. The position peaked at $131K in Q2 2023. 53 funds tracked by Wall St. Rank hold CARM as of Q2 2024.

  • CIBC Asset Management reported no remaining Carisma Therapeutics position as of Q2 2024 after selling out during the quarter.
  • CIBC Asset Management sold 14,971 Carisma Therapeutics shares in Q2 2024, an estimated $34K.
  • CIBC Asset Management first reported a position in Carisma Therapeutics in Q1 2023 and held it in 5 quarters.
  • CIBC Asset Management's Carisma Therapeutics position peaked at $131K in Q2 2023.
  • 53 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2024.

Based on CIBC Asset Management's 13F filing for Q2 2024, filed 1 Aug 2024.